Assan, Odilon https://orcid.org/0000-0001-6641-7907
Memoli, Victoria https://orcid.org/0000-0001-6866-6675
Guillaumie, Laurence https://orcid.org/0000-0003-1138-8285
Turcotte, Véronique https://orcid.org/0000-0002-0822-1479
Lemay, Martine https://orcid.org/0000-0001-7309-4149
Dionne, Anne https://orcid.org/0000-0002-7823-7636
Lemieux, Julie https://orcid.org/0000-0002-6168-320X
Provencher, Louise https://orcid.org/0009-0001-3463-8649
Gotay, Carolyn https://orcid.org/0000-0001-6861-5392
de Bruin, Marijn https://orcid.org/0000-0003-3100-6803
Guénette, Line https://orcid.org/0000-0001-9769-7550
Lauzier, Sophie https://orcid.org/0000-0002-7746-9208
Funding for this research was provided by:
Fonds d’enseignement et de recherche, Faculty of Pharmacy, Université Laval
Excellence Initiative of Aix-Marseille University - A*Midex
Aix-Marseille Institute of Public Health Sciences (ISSPAM-21-FLASH-00x)
Bourse de formation Desjardins pour la recherche et l’innovation de la Fondation du CHU de Québec-Université Laval
Canadian Institutes of Health Research (367503)
Fondation du CHU de Québec-Université Laval (3167 and 4024)
Fonds de recherche du Québec–Santé (Québec Health Research Fund) in partnership with the Unité Soutien SRAP du Québec (313085)
Article History
Received: 1 March 2024
Accepted: 10 April 2024
First Online: 4 May 2024
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Research Ethics Board of the CHU de Québec-Université Laval (MP-20–2018-4131).
: Informed written consent was obtained from all individual participants included in the study.
: Sophie Lauzier has received unrestricted research grants from Pfizer Canada and Eli Lilly for other studies not related to the one presented in this manuscript. Julie Lemieux has received honoraria from Novartis, Eli Lilly, Gilead, and Astra Zeneca not related to the one presented in this manuscript. All the other authors have no relevant financial or non-financial interests to disclose.